MOPP Chemotherapy for Treatment of Resistant Lymphoma in Dogs: A Retrospective Study of 117 Cases (1989-2000)

• Published in: Journal of veterinary internal medicine Vol. 16; no. 5; pp. 576 - 580
• Main Authors: Rassnick, Kenneth M., Mauldin, Glenna E., Al-Sarraf, Renee, Mauldin, G. Neal, Moore, Antony S., Mooney, Samantha C.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-09-2002
• Subjects: Animals; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Canine; Dog Diseases - drug therapy; Dogs; Drug Resistance, Neoplasm; Female; Lymphoma - drug therapy; Lymphoma - veterinary; Lymphosarcoma; Male; Mechlorethamine - adverse effects; Mechlorethamine - therapeutic use; Prednisone - adverse effects; Prednisone - therapeutic use; Procarbazine - adverse effects; Procarbazine - therapeutic use; Remission Induction; Rescue; Retrospective Studies; Treatment Outcome; Vincristine - adverse effects; Vincristine - therapeutic use
• ISSN: 0891-6640; 1939-1676
• DOI: 10.1111/j.1939-1676.2002.tb02390.x

The purpose of this retrospective study was to evaluate the efficacy and toxicity of the MOPP chemotherapy protocol (mechlor‐ethamine, vincristine, procarbazine, and prednisone) as a rescue regimen in dogs with lymphoma. One hundred seventeen dogs that had resistance to previously administered chemotherapy were evaluated. Before treatment with MOPP, all dogs received a median of 6 chemotherapy drugs for a median duration of 213 days. Thirty‐one percent (36 of 117) had a complete response (CR) to MOPP for a median of 63 days, and 34% (40 of 117) had a partial response (PR) for a median of 47 days. Sixteen percent (19 of 117) had stable disease (SD) for a median of 33 days. Predictors for response to MOPP were not identified. Gastrointestinal (GI) toxicity occurred in 28% (33 of 117) of the dogs, and 13% (15 dogs) required hospitalization. Five dogs developed septicemia, and 2 died as a result. MOPP was an effective treatment for dogs with resistant lymphoma and was well tolerated by the majority of affected dogs.